Telavancin Observational Use Registry (TOUR)

Trial Profile

Telavancin Observational Use Registry (TOUR)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Telavancin (Primary)
  • Indications Bacteraemia; Bone and joint infections; Endocarditis; Gram-positive infections; Nosocomial pneumonia; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Acronyms TOUR
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 25 Apr 2017 Preliminary results (n=279) presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 25 Apr 2017 Preliminary results (n=593) presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 25 Apr 2017 Preliminary results (n=36) assessing efficacy and safety of Telavancin in subset of patients with lower respiratory tract infections, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top